Atlas Trials

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Clinical trial NCT06443944 · AVAILABLE

Trial details

NCT number
NCT06443944
Sponsor
CG Oncology, Inc.
Status
AVAILABLE
Study type
EXPANDED_ACCESS
Non-Muscle Invasive Bladder CancerUrothelial CarcinomaUrologic CancerBladder Cancer

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.